1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wittschieben, J, Shivji, M K, Lalani, E, Stamp, G, Wood, R D. . Disruption of the developmentally regulated Rev3l gene causes embryonic lethality. In Current biology : CB, 10, 1217-20. doi:. https://pubmed.ncbi.nlm.nih.gov/11050392/
3. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
4. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
5. Zhang, S, Chen, H, Zhao, X, Wei, Q, Lu, D. 2012. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. In Oncogene, 32, 242-50. doi:10.1038/onc.2012.32. https://pubmed.ncbi.nlm.nih.gov/22349819/
6. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
智鼠故事 
